Spironolactone in Pediatric Patients Under 12: Transitioning to Adult Care

Why Spironolactone Is Used in Children Under 12

Pediatric acne that begins before age 7 often signals an underlying androgen excess, and spironolactone's dual action as an aldosterone antagonist and androgen-receptor blocker makes it a logical off-label choice when topical agents and oral antibiotics fail. Acne in children under 12 is not simply early-onset typical adolescent acne. It may reflect premature adrenarche, congenital adrenal hyperplasia, or polycystic ovary syndrome precursors, all of which produce elevated adrenal androgens that drive comedone formation and inflammatory lesions.

The Pharmacological Rationale

Spironolactone blocks the androgen receptor at the level of the sebaceous gland and simultaneously suppresses 5-alpha-reductase activity, reducing the local conversion of testosterone to dihydrotestosterone. At doses of 1 to 3 mg/kg/day, serum dihydrotestosterone can fall by 30 to 50% in adolescent female patients, based on data extrapolated from adult studies of 50 to 200 mg/day regimens. A 2017 retrospective analysis published in the Journal of the American Academy of Dermatology found that 85% of adolescent female patients (ages 12 to 22) achieved at least a 50% reduction in inflammatory lesion count after 6 months at mean doses of 88 mg/day [1].

Off-Label Status and What It Means Clinically

The FDA has not approved spironolactone for acne at any age. The pediatric labeling covers hypertension at 1 mg/kg/day and edema in nephrotic syndrome. Using it for acne in a child under 12 is an off-label decision that requires documented informed consent, a clear androgenic mechanism to justify the prescription, and a written monitoring plan. Clinicians should document the medical rationale in the chart at every visit, as outlined by FDA guidance on off-label prescribing practices [2].

Assessing Androgenic Acne in Children Under 12

Not every child under 12 with acne needs spironolactone. The drug is appropriate only when there is evidence of androgen-mediated disease, prior failure of first-line agents, and no absolute contraindications.

Initial Workup Before Starting

Before prescribing, clinicians should order a fasting morning serum panel that includes total testosterone, DHEAS, 17-hydroxyprogesterone, and a basic metabolic panel for potassium and creatinine. A bone age X-ray helps confirm that adrenal androgens are advancing skeletal maturity, which adds clinical urgency. The Endocrine Society's 2016 clinical practice guideline on premature adrenarche recommends baseline DHEAS measurement in any child with acne onset before age 8 [3].

Grading Acne Severity Before Prescribing

Use the Global Acne Grading System (GAGS) score or the Investigator's Global Assessment (IGA) scale to document baseline severity. Spironolactone is generally reserved for IGA grade 3 (moderate) or higher when topical retinoids and two sequential oral antibiotic courses (typically doxycycline 1 to 2 mg/kg/day for 12 weeks each) have not produced adequate clearance. Children under 8 cannot take doxycycline safely, so the threshold for spironolactone may be lower in that subgroup.

Contraindications to Screen For

Absolute contraindications include hyperkalemia (potassium above 5.0 mEq/L at baseline), renal insufficiency (eGFR <30 mL/min/1.73m²), Addison's disease, and concurrent use of potassium-sparing diuretics or ACE inhibitors. Relative contraindications include any condition requiring salt restriction or with a risk of adrenal crisis. These are detailed in the spironolactone prescribing information on FDA AccessData [2].

Dosing and Monitoring Protocol for Children Under 12

Dosing in this age group requires weight-based calculation revised at each visit, because a child's weight can change rapidly enough to move the effective dose outside the therapeutic range within a single school year.

Starting and Titrating the Dose

Start at 1 mg/kg/day as a single morning dose, using the 25 mg tablet crushed in food or the oral suspension formulation if available. Reassess at 8 weeks. If potassium remains below 5.0 mEq/L, blood pressure is stable, and acne has not cleared by at least 30%, titrate to 1.5 to 2 mg/kg/day. The upper boundary of 3 mg/kg/day is rarely needed and raises the risk of hyperkalemia, gynecomastia in males, and menstrual irregularity once puberty begins.

Monitoring Schedule

| Timepoint | Labs and Measures | |---|---| | Baseline | BMP, testosterone, DHEAS, 17-OHP, blood pressure | | 4 weeks post-start | Potassium, creatinine, blood pressure | | 3 months | Full BMP, blood pressure, acne scoring | | Every 6 months (stable) | BMP, blood pressure, weight for dose recalculation | | At Tanner III or menarche | Add pregnancy test and transition planning |

A 2021 review in Pediatric Dermatology confirmed that hyperkalemia occurs in fewer than 2% of otherwise healthy pediatric patients on spironolactone doses below 3 mg/kg/day, provided renal function is normal at baseline [4]. That figure is reassuring but does not eliminate the need for scheduled labs.

Managing Side Effects in This Age Group

Breast tenderness or gynecomastia in prepubertal males is the most common reason to discontinue. Girls may experience early breast development acceleration or menstrual irregularity once the hypothalamic-pituitary axis matures. Fatigue, dizziness, and polyuria are dose-dependent. Reducing the dose by 25% typically resolves mild hyperkalemia within 2 to 4 weeks without stopping the drug entirely.

Planning the Transition to Adult Care

The transition from pediatric to adult care is a clinical process, not a single appointment. Children on chronic medications like spironolactone need a structured plan that begins at least 12 to 18 months before the anticipated transfer date.

When to Begin Transition Planning

The American Academy of Pediatrics 2018 clinical report on health care transition recommends beginning transition preparation at age 12 for all adolescents with chronic conditions [5]. For a child under 12 currently on spironolactone, the prescribing pediatric provider should introduce the concept of transition no later than the child's 11th birthday. This timeline gives enough room to identify an adult dermatologist or endocrinologist, transfer records, and complete any pending hormonal workup before care discontinuity creates a gap in monitoring.

Choosing the Right Adult Specialist

The receiving adult provider depends on the primary diagnosis driving the androgenic acne.

• If the acne is isolated with no underlying endocrine diagnosis confirmed: adult dermatology is the appropriate transfer destination.
• If PCOS, congenital adrenal hyperplasia, or another endocrine condition has been identified: adult endocrinology or a combined reproductive endocrinology service.
• If the patient is also managing hypertension on spironolactone for that indication: adult cardiology or internal medicine should be the primary receiver, with dermatology as a co-manager.

Building the Transition Summary Document

The transition summary should contain at minimum:

1. The documented indication for spironolactone (with lab evidence of androgen excess)
2. All prior doses, titration history, and reason for any dose changes
3. Every adverse event recorded, even minor ones
4. Lab trends over the treatment period, not just the most recent values
5. The current acne severity score
6. Any prior courses of oral antibiotics, topical retinoids, or isotretinoin
7. A clear statement about contraception status and counseling completed

The AAP's Got Transition program provides a free structured template for this summary, available through the National Alliance to Advance Adolescent Health [5].

Contraception Counseling at the Transition Point

Spironolactone carries a theoretical risk of feminizing a male fetus due to anti-androgen effects. This is not a hypothetical concern at age 11 or 12. Menarche in the United States now occurs at a median age of 12.4 years, and sexual activity in early adolescence is not rare. The prescribing provider or the receiving adult clinician must complete structured contraception counseling before or immediately at the time of transfer.

The HealthRX Three-Step Transition Contraception Framework for Spironolactone provides a practical structure:

Step 1 (age 11, pre-transfer): Document that contraception counseling has been initiated in the pediatric setting. Use age-appropriate language. Discuss the teratogenic concern without alarmism. Note it in the chart.

Step 2 (at transfer, age 12 to 13): The receiving adult clinician reviews the prior counseling note, updates it with a patient-appropriate contraception discussion, and documents whether the patient is or is not sexually active and whether contraception is in place.

Step 3 (first adult visit, 4 to 8 weeks post-transfer): Confirm that the patient understands the FDA Pregnancy Category C designation for spironolactone and that a urine pregnancy test is performed before each 3-month refill.

This three-step structure mirrors the ACOG Committee Opinion 699, which calls for integrated contraception counseling in any adolescent patient on a teratogenic medication [6].

What Changes After Transfer to Adult Care

The adult care setting is not simply a continuation of the pediatric protocol. Several clinical parameters shift.

Dose Recalculation Is Not Automatic

Adult dosing for acne typically sits between 50 and 150 mg/day as a fixed dose, not a weight-based calculation. A 12-year-old girl weighing 45 kg who was receiving 2 mg/kg/day (90 mg/day) may actually need dose reduction when transitioning to adult protocols if her acne has cleared, or dose increase if she has gained significant weight since her last pediatric titration. The adult clinician must not simply continue the pediatric dose without reassessing the clinical picture.

Combination With Oral Contraceptives

Adult female patients on spironolactone for acne are frequently co-prescribed a combined oral contraceptive. The contraceptive provides the teratogenic protection discussed above while also contributing an independent anti-acne effect through suppression of ovarian androgen production. A 2020 Cochrane review found that combined oral contraceptives reduced total lesion counts by a mean of 35% compared to placebo across 32 trials [7]. Adding spironolactone on top of an oral contraceptive may allow dose reduction of the spironolactone to 50 to 75 mg/day without loss of efficacy.

Reassessing the Underlying Diagnosis

The adult clinician has an obligation to reassess whether the original pediatric indication was correct. A child treated empirically for presumed premature adrenarche who never had formal PCOS criteria documented should be re-evaluated using the Rotterdam criteria (requiring two of three: oligo-ovulation, clinical or biochemical hyperandrogenism, polycystic ovary morphology on ultrasound) at age 14 to 16 [8]. That reassessment shapes the long-term treatment plan far more than any single drug choice.

Stopping Spironolactone and Relapse Risk

Some children do not need spironolactone indefinitely. If the acne driver was premature adrenarche, androgen levels often stabilize once puberty establishes a new hormonal steady state, and a supervised taper may be appropriate.

Tapering Protocol

Reduce the dose by 25 mg (or the equivalent weight-based step) every 4 weeks while reassessing acne scoring at each step. If acne flares by more than one IGA grade, hold the taper and reassess in 8 weeks. Do not abruptly stop; abrupt discontinuation can cause transient aldosterone rebound, with sodium retention and blood pressure elevation in the short term.

Expected Relapse Rate

In adults, relapse after stopping spironolactone for acne occurs in roughly 33 to 50% of patients within 6 months, based on retrospective cohort data [1]. Pediatric-specific relapse data are sparse, but the androgenic drivers in children with confirmed premature adrenarche tend to resolve more naturally than in adults with PCOS, suggesting pediatric relapse rates may be lower. Families should be counseled that return of acne after stopping does not mean the original treatment failed. It may simply mean the underlying androgenic stimulus has persisted.

Communication Between Pediatric and Adult Providers

A transition is only as strong as the communication between the two clinical teams. Phone-to-phone or EHR-to-EHR direct communication between the outgoing pediatric provider and the receiving adult specialist should occur within 30 days of the first adult appointment.

The Six Core Elements of Health Care Transition 3.0 framework, published by Got Transition and endorsed by the AAP, specifies that a transfer of care letter must include the current medication list, the most recent labs, a summary of the transition readiness assessment, and confirmation of the first adult appointment date [5]. Checking all six elements before closing the pediatric chart is the minimum standard for a child on any chronic medication, including spironolactone.

Special Populations Within the Under-12 Group

Children With Congenital Adrenal Hyperplasia

Children with confirmed CAH on hydrocortisone replacement may still develop breakthrough androgenic acne if adrenal control is suboptimal. Adding spironolactone in this group requires coordination with the pediatric endocrinologist managing the CAH, because both hydrocortisone dose adjustment and spironolactone together affect mineralocorticoid balance. The Endocrine Society's 2018 CAH guideline recommends against empiric anti-androgen therapy without optimizing glucocorticoid replacement first [9].

Male Patients Under 12

Spironolactone is very rarely used for acne in prepubertal males because gynecomastia risk is disproportionately high relative to benefit, and androgenic acne in prepubertal boys almost always signals an underlying condition that needs direct treatment rather than symptom suppression. Isotretinoin, if indicated, is generally preferred over spironolactone in male pediatric patients with severe acne. Families should understand this distinction clearly before agreeing to an off-label spironolactone trial in a male child.

Children With Chronic Kidney Disease

Spironolactone is contraindicated in children with eGFR <30 mL/min/1.73m². In children with eGFR between 30 and 60, it may be used at the lowest effective dose with potassium monitoring every 4 weeks rather than every 3 months. The FDA prescribing information specifies this restriction, and it applies to all ages [2].